Ambiq Apollo510 Delivers 30x Power Efficiency Improvement to Unleash Endpoint AI
Globe Newswire26-03-2024, 19:15
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00